Find and Pitch Jounalists, Get Your Story Covered

Tags: cancer, cancer diagnosis, cell-free, circulating tumor DNA, DNA, liquid biopsy, next generation sequencing, sequencing cancer, cell biology, circulating tumor cells, microfluidics Institute of Cancer Research\The Royal Marsden NHS Foundation Trust\RADSARC-R \

	Profile	Recent Articles on Subject
1	<em>The Scientist</em> Staff The Scientist Exploring Life, Inspiring Innovation. scienceinnovation	Advances in Cancer Therapies and Diagnostics - about 2 months ago Exploring How Sequencing and Omics are Shaping Disease Research - 4 months ago The Next Frontier: Circulating Tumor Cells and Liquid Biopsies - 4 months ago Enhanced Sequencing Results from Liquid Biopsies - 5 months ago
2	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	4 companies to watch in the accelerating gene editing race - about 2 months ago Mining clues from a library of brain tissue samples, Cerevance takes a precision approach to CNS disorders - 7 months ago Astellas’ science chief on the leap into new technologies - about 1 year ago The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing. - about 1 year ago
3	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	Biopharma leaders lay out vision for the future of blood cancer treatment - 3 months ago
4	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	Biopharma leaders lay out vision for the future of blood cancer treatment - 3 months ago
5	Angus Chen STAT News Undignified, unfunny journalist. Health, cancer coverage at STAT News. journalismhealthcancer researchSTAT News	Biopharma leaders lay out vision for the future of blood cancer treatment - 3 months ago STAT+: When a cancer drug fails, oncologists often fly blind. A precision technique might light the way - 11 months ago
6	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Biopharma leaders lay out vision for the future of blood cancer treatment - 3 months ago STAT+: More tumult at BIO amid the company’s fourth CEO in four years - 9 months ago The latest updates on cancer research from the weekend - 11 months ago New data on liquid biopsy for colorectal cancer detection still underwhelms - 11 months ago What happens when an approved drug doesn’t work? - 12 months ago The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive - about 1 year ago CRISPR is about to make history. Here’s the 5-minute rundown of what to expect - about 1 year ago A new algorithm unveils CRISPR ‘treasure trove’ - about 1 year ago Want a biotech buyout? Target cancer - over 1 year ago
7	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Advances in the Treatment of Resectable NSCLC: Key Insights From CheckMate 77T, NEOSTAR, and CA209-159 Trials - 5 months ago
8	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	23andMe inches closes to cancer immunotherapy, guided by its genetic database - 6 months ago Now a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters - 10 months ago This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain - about 1 year ago A biotech tackles drug discovery with transcription factor know-how - over 1 year ago
9	Susan Kelly MedTech Dive Leader, teacher, learner. St. John's youthtech sector	Grail to shed 350 workers in restructuring - 6 months ago Roundup: Illumina’s long goodbye to cancer test maker Grail - about 1 year ago Illumina prepares to divest Grail with Form 10 filing - about 1 year ago Illumina explores options for Grail, hires advisers - over 1 year ago
10	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - 6 months ago 4 offbeat biotechs making a splash in the life sciences - 10 months ago Black Diamond looks to outwit cancer mutations - 12 months ago

Journalists covering cancer research, cancer therapeutics, CRISPR, liquid biopsy, sequencing